论文部分内容阅读
目的探究拉米夫定和阿德福韦酯联合治疗乙肝肝硬化的治疗效果。方法 90例乙肝肝硬化患者随机分成甲、乙、丙三组各30例,甲组患者使用拉米夫定治疗,乙组患者使用阿德福韦酯治疗,丙组患者使用两种药物联合治疗,观察比较三组患者的病毒应答、谷丙转氨酶(ALT)、血清白蛋白(ALB)等生化指标。结果丙组患者联合用药,其病毒学应答在治疗后第3、6个月明显高于其他两组,差异具有统计学意义(P<0.05);三组患者的ALT、ALB、总胆红素(TBiL)等均有所改善,但丙组联合用药最明显,其前后比较差异具有统计学意义(P<0.05)。结论拉米夫定和阿德福韦酯联合使用能够明显提高乙肝肝硬化的临床疗效,而且耐药性好,减少患者经济负担,值得临床中研究推广应用。
Objective To investigate the therapeutic effect of lamivudine and adefovir dipivoxil in the treatment of hepatitis B cirrhosis. Methods Ninety patients with hepatitis B cirrhosis were randomly divided into three groups: group A, group B and group C, with lamivudine in group A, adefovir dipivoxil in group B and combination of two drugs in group C The biochemical indexes such as virus response, ALT and ALB in the three groups were observed and compared. Results In combination group C, the virological response was significantly higher at 3 and 6 months after treatment than the other two groups (P <0.05). ALT, ALB, total bilirubin (TBiL) were improved, but the combination group C the most obvious, before and after the difference was statistically significant (P <0.05). Conclusion The combination of lamivudine and adefovir dipivoxil can significantly improve the clinical efficacy of hepatitis B cirrhosis, and good drug resistance and reduce the economic burden on patients, it is worth to promote the clinical application.